<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Chimeric antigen receptor - Wikipedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Chimeric_antigen_receptor","wgTitle":"Chimeric antigen receptor","wgCurRevisionId":879808930,"wgRevisionId":879808930,"wgArticleId":1624240,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Webarchive template wayback links","Wikipedia articles that are too technical from April 2018","All articles that are too technical","Articles needing expert attention from April 2018","All articles needing expert attention","Wikipedia articles in need of updating from October 2016","All Wikipedia articles in need of updating","Articles needing additional references from August 2017","All articles needing additional references","All articles with unsourced statements","Articles with unsourced statements from December 2017","Immune system","T cells","Cancer treatments","Leukemia","Lymphoma","Gene therapy"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Chimeric_antigen_receptor","wgRelevantArticleId":1624240,"wgRequestId":"XEyGMQpAAEMAABuE5UQAAAAS","wgCSPNonce":false,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgWikiEditorEnabledModules":[],"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsShouldSendModuleToUser":true,"wgPopupsConflictsWithNavPopupGadget":false,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en","usePageImages":true,"usePageDescriptions":true},"wgMFExpandAllSectionsUserOption":true,"wgMFEnableFontChanger":true,"wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgWMESchemaEditAttemptStepOversample":false,"wgPoweredByHHVM":true,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgCentralNoticeCookiesToDelete":[],"wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgWikibaseItemId":"Q5099363","wgScoreNoteLanguages":{"arabic":"العربية","catalan":"català","deutsch":"Deutsch","english":"English","espanol":"español","italiano":"italiano","nederlands":"Nederlands","norsk":"norsk","portugues":"português","suomi":"suomi","svenska":"svenska","vlaams":"West-Vlams"},"wgScoreDefaultNoteLanguage":"nederlands","wgCentralAuthMobileDomain":false,"wgCodeMirrorEnabled":true,"wgVisualEditorToolbarScrollOffset":0,"wgVisualEditorUnsupportedEditParams":["undo","undoafter","veswitched"],"wgEditSubmitButtonLabelPublish":true,"oresWikiId":"enwiki","oresBaseUrl":"http://ores.discovery.wmnet:8081/","oresApiVersion":3});mw.loader.state({"ext.gadget.charinsert-styles":"ready","ext.globalCssJs.user.styles":"ready","ext.globalCssJs.site.styles":"ready","site.styles":"ready","noscript":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","ext.globalCssJs.site":"ready","user":"ready","user.options":"ready","user.tokens":"loading","ext.cite.styles":"ready","mediawiki.legacy.shared":"ready","mediawiki.legacy.commonPrint":"ready","mediawiki.toc.styles":"ready","wikibase.client.init":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","ext.wikimediaBadges":"ready","ext.3d.styles":"ready","mediawiki.skinning.interface":"ready","skins.vector.styles":"ready"});mw.loader.implement("user.tokens@0tffind",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.watchlist-notice","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.extra-toolbar-buttons","ext.gadget.switcher","ext.centralauth.centralautologin","mmv.head","mmv.bootstrap.autostart","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.eventlogger","ext.uls.init","ext.uls.compactlinks","ext.uls.interface","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp","skins.vector.js"];mw.loader.load(RLPAGEMODULES);});</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.3d.styles%7Cext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.skinning.interface%7Cmediawiki.toc.styles%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.charinsert-styles&amp;only=styles&amp;skin=vector"/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.33.0-wmf.14"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Chimeric_antigen_receptor"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Chimeric_antigen_receptor"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/load.php?debug=false&amp;lang=en&amp;modules=html5shiv&amp;only=scripts&amp;skin=vector&amp;sync=1"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Chimeric_antigen_receptor rootpage-Chimeric_antigen_receptor skin-vector action-view">		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="siteNotice" class="mw-body-content"><!-- CentralNotice --></div><div class="mw-indicators mw-body-content">
</div>
<h1 id="firstHeading" class="firstHeading" lang="en">Chimeric antigen receptor</h1>			<div id="bodyContent" class="mw-body-content">
				<div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div>				<div id="contentSub"></div>
				<div id="jump-to-nav"></div>				<a class="mw-jump-link" href="#mw-head">Jump to navigation</a>
				<a class="mw-jump-link" href="#p-search">Jump to search</a>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><table class="box-Technical plainlinks metadata ambox ambox-style ambox-technical" role="presentation"><tbody><tr><td class="mbox-image"><div style="width:52px"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png" decoding="async" width="40" height="40" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/60px-Edit-clear.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/80px-Edit-clear.svg.png 2x" data-file-width="48" data-file-height="48" /></div></td><td class="mbox-text"><div class="mbox-text-span">This article <b>may be too technical for most readers to understand</b>. Please <a class="external text" href="//en.wikipedia.org/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit">help improve it</a> to <a href="/wiki/Wikipedia:Make_technical_articles_understandable" title="Wikipedia:Make technical articles understandable">make it understandable to non-experts</a>, without removing the technical details.  <small class="date-container"><i>(<span class="date">April 2018</span>)</i></small><small class="hide-when-compact"><i> (<a href="/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>
<p><b>Chimeric antigen receptors</b> (<b>CARs</b>, also known as <b>chimeric immunoreceptors</b>, <b>chimeric T cell receptors</b> or <b>artificial T cell receptors</b>) are <a href="/wiki/Receptor_(biochemistry)" title="Receptor (biochemistry)">receptor</a> proteins that have been engineered to give <a href="/wiki/T_cell" title="T cell">T cells</a> the new ability to target a specific <a href="/wiki/Protein" title="Protein">protein</a>. The receptors are <a href="/wiki/Fusion_protein" title="Fusion protein">chimeric</a> because they combine both antigen-binding and T-cell activating functions into a single receptor.
</p><p>CAR-T <a href="/wiki/Cell_therapy" title="Cell therapy">cell therapy</a> uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors.<sup id="cite_ref-newsweek_1-0" class="reference"><a href="#cite_note-newsweek-1">&#91;1&#93;</a></sup> CAR-T cells can be either derived from T cells in a patient's own blood (<a href="/wiki/Autologous" class="mw-redirect" title="Autologous">autologous</a>) or derived from the T cells of another healthy donor (<a href="/wiki/Allogenic" class="mw-redirect" title="Allogenic">allogenic</a>). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors.   For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup> 
</p><p>After CAR-T cells are infused into a patient, they act as a "living drug" against cancer cells.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup> When they come in contact with their targeted antigen on a cell, CAR-T cells bind to it and become activated, then proceed to proliferate and become <a href="/wiki/Cytotoxic" class="mw-redirect" title="Cytotoxic">cytotoxic</a>.<sup id="cite_ref-Hartmann_4-0" class="reference"><a href="#cite_note-Hartmann-4">&#91;4&#93;</a></sup> CAR-T cells destroy cells through several mechanisms, including extensive stimulated cell proliferation, increasing the degree to which they are toxic to other living cells (cytotoxicity), and by causing the increased secretion of factors that can affect other cells such as <a href="/wiki/Cytokine" title="Cytokine">cytokines</a>, <a href="/wiki/Interleukin" title="Interleukin">interleukins</a>, and growth factors.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup> 
</p>
<div id="toc" class="toc"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2>Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Use_in_cancer"><span class="tocnumber">1</span> <span class="toctext">Use in cancer</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Preparation"><span class="tocnumber">1.1</span> <span class="toctext">Preparation</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Safety_concerns"><span class="tocnumber">1.2</span> <span class="toctext">Safety concerns</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Structure"><span class="tocnumber">2</span> <span class="toctext">Structure</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#Ectodomain"><span class="tocnumber">2.1</span> <span class="toctext">Ectodomain</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Transmembrane_domain"><span class="tocnumber">2.2</span> <span class="toctext">Transmembrane domain</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Endodomain"><span class="tocnumber">2.3</span> <span class="toctext">Endodomain</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#History"><span class="tocnumber">3</span> <span class="toctext">History</span></a>
<ul>
<li class="toclevel-2 tocsection-9"><a href="#Smart_T_cell"><span class="tocnumber">3.1</span> <span class="toctext">Smart T cell</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#SMDC_adaptor_technology"><span class="tocnumber">3.2</span> <span class="toctext">SMDC adaptor technology</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Clinical_studies"><span class="tocnumber">4</span> <span class="toctext">Clinical studies</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#FDA_approvals"><span class="tocnumber">4.1</span> <span class="toctext">FDA approvals</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-13"><a href="#See_also"><span class="tocnumber">5</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#References"><span class="tocnumber">6</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-15"><a href="#External_links"><span class="tocnumber">7</span> <span class="toctext">External links</span></a></li>
</ul>
</div>

<h2><span class="mw-headline" id="Use_in_cancer">Use in cancer</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=1" title="Edit section: Use in cancer">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:CAR_T-cell_Therapy.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b6/CAR_T-cell_Therapy.svg/220px-CAR_T-cell_Therapy.svg.png" decoding="async" width="220" height="69" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b6/CAR_T-cell_Therapy.svg/330px-CAR_T-cell_Therapy.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b6/CAR_T-cell_Therapy.svg/440px-CAR_T-cell_Therapy.svg.png 2x" data-file-width="512" data-file-height="160" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:CAR_T-cell_Therapy.svg" class="internal" title="Enlarge"></a></div>The diagram above represents the process of chimeric antigen receptor T-cell therapy (CAR), this is a method of immunotherapy, which is a growing practice in the treatment of cancer. The final result should be a  production of equipped T-cells that can recognize and fight the infected cancer cells in the body. <br />1. T-cells (represented by objects labeled as ’t’) are removed from the patient's blood.<br />2. Then in a lab setting the gene that encodes for the specific antigen receptors are incorporated into the T-cells.<br />3. Thus producing the CAR receptors (labeled as c) on the surface of the cells. <br />4. The newly modified T-cells are then further harvested and grown in the lab.<br />5. After a certain time period, the engineered T-cells are infused back into the patient.</div></div></div>
<table class="box-Update plainlinks metadata ambox ambox-content ambox-Update" role="presentation"><tbody><tr><td class="mbox-image"><div style="width:52px"><img alt="Ambox current red.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/98/Ambox_current_red.svg/42px-Ambox_current_red.svg.png" decoding="async" width="42" height="34" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/98/Ambox_current_red.svg/63px-Ambox_current_red.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/98/Ambox_current_red.svg/84px-Ambox_current_red.svg.png 2x" data-file-width="360" data-file-height="290" /></div></td><td class="mbox-text"><div class="mbox-text-span">This section needs to be <b>updated</b>.<span class="hide-when-compact"> Please update this article to reflect recent events or newly available information.</span>  <small class="date-container"><i>(<span class="date">October 2016</span>)</i></small></div></td></tr></tbody></table>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:CAR-Engineered_T-Cell_Adoptive_Transfer.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/CAR-Engineered_T-Cell_Adoptive_Transfer.jpg/220px-CAR-Engineered_T-Cell_Adoptive_Transfer.jpg" decoding="async" width="220" height="130" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/CAR-Engineered_T-Cell_Adoptive_Transfer.jpg/330px-CAR-Engineered_T-Cell_Adoptive_Transfer.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/CAR-Engineered_T-Cell_Adoptive_Transfer.jpg/440px-CAR-Engineered_T-Cell_Adoptive_Transfer.jpg 2x" data-file-width="1280" data-file-height="758" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:CAR-Engineered_T-Cell_Adoptive_Transfer.jpg" class="internal" title="Enlarge"></a></div>Depiction of adoptive cell transfer therapy with CAR-engineered T cells</div></div></div>
<p><a href="/wiki/Adoptive_cell_transfer" title="Adoptive cell transfer">Adoptive transfer</a> of T cells expressing chimeric antigen receptors is a promising anti-cancer therapeutic as CAR-modified T cells can be engineered to target virtually any <a href="/wiki/Tumor_associated_antigen" class="mw-redirect" title="Tumor associated antigen">tumor associated antigen</a>. There is great potential for this approach to improve patient-specific cancer therapy in a profound way. Following collection of a patient's T cells, the cells are genetically engineered to express CARs specifically directed toward antigens on the patient's tumor cells, then infused back into the patient.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">&#91;6&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Preparation">Preparation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=2" title="Edit section: Preparation">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The first step in the introduction of CAR-T cells into the body of a patient is the removal of activated leukocytes from the blood in a process known as <a href="/wiki/Leukocyte_apheresis" title="Leukocyte apheresis">leukocyte apheresis</a>. The leukocytes are removed using a blood cell separator. The patient’s autologous <a href="/wiki/Peripheral_blood_mononuclear_cell" title="Peripheral blood mononuclear cell">peripheral blood mononuclear cells</a> (PBMC) are then separated and collected from the buffy coat that forms.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup> The products of leukocyte apheresis are then transferred into a cell processing center. In the cell processing center, specific T-cells are activated in a certain environment in which they can actively proliferate. The cells are activated using a type of cytokine called an <a href="/wiki/Interleukin" title="Interleukin">interleukin</a>, specifically Inter-Leukin 2 (IL-2) as well as anti-<a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a> <a href="/wiki/Antibody" title="Antibody">antibodies</a>.<sup id="cite_ref-:0_8-0" class="reference"><a href="#cite_note-:0-8">&#91;8&#93;</a></sup>
</p><p>The T-cells are then transfected with CD19 CAR genes by either an integrating <a href="/wiki/Gammaretrovirus" title="Gammaretrovirus">gammaretrovirus</a> (RV) or by <a href="/wiki/Lentivirus" title="Lentivirus">lentivirus</a> (LV) vectors. These vectors are very safe in modern times due to a partial deletion of the U3 region.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup> The patient undergoes lymphodepletion chemotherapy prior to the introduction of the engineered CD CAR-T cells.<sup id="cite_ref-Hartmann2017_10-0" class="reference"><a href="#cite_note-Hartmann2017-10">&#91;10&#93;</a></sup> The depletion of the number of circulating leukocytes in the patient upregulates the number of cytokines that are produced which help to promote the expansion of the engineered CAR-T cell.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Safety_concerns">Safety concerns</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=3" title="Edit section: Safety concerns">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>CAR-T cells are undoubtedly a major breakthrough in cancer treatment. However, there are still expected and unexpected toxicities that result from CAR-T cells being introduced into the body. These toxicities include <a href="/wiki/Cytokine_release_syndrome" title="Cytokine release syndrome">cytokine release syndrome</a>, neurological toxicity, on-target/off-tumor recognition, <a href="/wiki/Insertional_mutagenesis" title="Insertional mutagenesis">insertional mutagenesis</a>, and <a href="/wiki/Anaphylaxis" title="Anaphylaxis">anaphylaxis</a>.<sup id="cite_ref-Hartmann2017_10-1" class="reference"><a href="#cite_note-Hartmann2017-10">&#91;10&#93;</a></sup>
</p><p>Cytokine release syndrome (CRS) is a condition in which the immune system is activated and releases an increased number of inflammatory <a href="/wiki/Cytokine" title="Cytokine">cytokines</a>. The clinical manifestations of this syndrome include high fever, fatigue, <a href="/wiki/Myalgia" title="Myalgia">myalgia</a>, nausea, <a href="/wiki/Tachycardia" title="Tachycardia">tachycardia</a>, capillary leakages, cardiac dysfunction, hepatic failure, and renal impairment.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup>
</p><p>The neurological toxicity associated with CAR-T cells have clinical manifestations that include delirium, the partial loss of the ability to speak a coherent language while still having the ability to interpret language (<a href="/wiki/Expressive_aphasia" title="Expressive aphasia">expressive aphasia</a>), lowered alertness (<a href="/wiki/Obtundation" title="Obtundation">obtundation</a>), and seizures.<sup id="cite_ref-:2_13-0" class="reference"><a href="#cite_note-:2-13">&#91;13&#93;</a></sup> During some clinical trials deaths caused by neurotoxicity have occurred. The main cause of death from neurotoxicity is <a href="/wiki/Cerebral_edema" title="Cerebral edema">cerebral edema</a>. In a study carried out by <a href="/wiki/Juno_Therapeutics" title="Juno Therapeutics">Juno Therapeutics</a>, Inc., five patients enrolled in the trial died as a result of cerebral edema. Two of the patients were treated with <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a> alone and the remaining three were treated with a combination of cyclophosphamide and <a href="/wiki/Fludarabine" title="Fludarabine">fludarabine</a>.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup> In another clinical trial sponsored by the <a href="/wiki/Fred_Hutchinson_Cancer_Research_Center" title="Fred Hutchinson Cancer Research Center">Fred Hutchinson Cancer Research Center</a>, there was one reported case of irreversible and fatal neurological toxicity 122 days after the administration of CAR-T cells.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>
</p><p>On-target/off-tumor recognition occurs when the CAR-T cell recognizes the correct <a href="/wiki/Antigen" title="Antigen">antigen</a>, but the antigen is expressed on healthy, non-pathogenic tissue. This results in the CAR-T cells attacking non-tumor tissue, such as healthy B cells that express CD19. The severity of this adverse effect can vary from B-cell <a href="/wiki/Aplasia" title="Aplasia">aplasia</a> to extreme toxicity leading to death.<sup id="cite_ref-:0_8-1" class="reference"><a href="#cite_note-:0-8">&#91;8&#93;</a></sup>
</p><p>Anaphylaxis is an expected side effect, as the CAR is made with a foreign <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> and as a result, invokes an immune response. 
</p><p>There is also a potential for insertional mutagenesis, which can occur when using a virus to insert the CAR vector DNA into a host T cell. Lentiviral (LV) vectors carry a lower risk than retroviral (RV) vectors. However, both have the potential to be oncogenic.
</p><p>Because it is a relatively new treatment, there is little data about the long-term effects of CAR-T cell therapy. There are still concerns about long-term survival as well as pregnancy complications in female patients treated with CAR-T cells.<sup id="cite_ref-:2_13-1" class="reference"><a href="#cite_note-:2-13">&#91;13&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Structure">Structure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=4" title="Edit section: Structure">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="box-Unreferenced_section plainlinks metadata ambox ambox-content ambox-Unreferenced" role="presentation"><tbody><tr><td class="mbox-image"><div style="width:52px"><a href="/wiki/File:Question_book-new.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png" decoding="async" width="50" height="39" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x" data-file-width="512" data-file-height="399" /></a></div></td><td class="mbox-text"><div class="mbox-text-span">This section <b>does not <a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources">cite</a> any <a href="/wiki/Wikipedia:Verifiability" title="Wikipedia:Verifiability">sources</a></b>.<span class="hide-when-compact"> Please help <a class="external text" href="//en.wikipedia.org/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit">improve this section</a> by <a href="/wiki/Help:Introduction_to_referencing_with_Wiki_Markup/1" title="Help:Introduction to referencing with Wiki Markup/1">adding citations to reliable sources</a>. Unsourced material may be challenged and <a href="/wiki/Wikipedia:Verifiability#Burden_of_evidence" title="Wikipedia:Verifiability">removed</a>.</span>  <small class="date-container"><i>(<span class="date">August 2017</span>)</i></small><small class="hide-when-compact"><i> (<a href="/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>
<p>CAR-T cells create a link between an extracellular <a href="/wiki/Ligand" title="Ligand">ligand</a> recognition domain to an intracellular signalling molecule which in turn activates T cells. The extracellular ligand recognition domain is usually a single-chain variable fragment (scFv). CARs are composed of three regions: the <a href="/wiki/Ectodomain" title="Ectodomain">ectodomain</a>, the <a href="/wiki/Transmembrane_domain" title="Transmembrane domain">transmembrane domain</a> and the <a href="https://en.wiktionary.org/wiki/endodomain" class="extiw" title="wikt:endodomain">endodomain</a>.
</p>
<div class="thumb tright"><div class="thumbinner" style="width:182px;"><a href="/wiki/File:CAR_cartoon.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/CAR_cartoon.png/180px-CAR_cartoon.png" decoding="async" width="180" height="231" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/47/CAR_cartoon.png/270px-CAR_cartoon.png 1.5x, //upload.wikimedia.org/wikipedia/commons/4/47/CAR_cartoon.png 2x" data-file-width="319" data-file-height="410" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:CAR_cartoon.png" class="internal" title="Enlarge"></a></div>Different components of an artificial <a href="/wiki/T-cell_receptor" title="T-cell receptor">TCR</a></div></div></div>
<h3><span class="mw-headline" id="Ectodomain">Ectodomain</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=5" title="Edit section: Ectodomain">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The ectodomain is the region of the receptor that is exposed to the extracellular fluid and consists of 3 components: a signalling peptide, an antigen recognition region and a spacer.
</p><p>A <a href="/wiki/Signal_peptide" title="Signal peptide">signal peptide</a> directs the nascent protein into the <a href="/wiki/Endoplasmic_reticulum" title="Endoplasmic reticulum">endoplasmic reticulum</a>. The signal protein in CAR is called a <a href="/wiki/Single-chain_variable_fragment" title="Single-chain variable fragment">single-chain variable fragment</a> (scFv),<sup id="cite_ref-:3_16-0" class="reference"><a href="#cite_note-:3-16">&#91;16&#93;</a></sup> a type of protein known as a fusion protein or chimeric protein. A fusion protein is a protein that is formed by merging two or more genes that code originally for different proteins but when they are translated in the cell, the translation produces one or more <a href="/wiki/Polypeptides" class="mw-redirect" title="Polypeptides">polypeptides</a> with functional properties derived for each of the original genes.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup>
</p><p>A scFv is a chimeric protein made up of the light and heavy chains of <a href="/wiki/Immunoglobin" class="mw-redirect" title="Immunoglobin">immunoglobins</a> connected with a short linker peptide. The linker consists of <a href="/wiki/Hydrophilic" class="mw-redirect" title="Hydrophilic">hydrophilic</a> residues with stretches of <a href="/wiki/Glycine" title="Glycine">glycine</a> and <a href="/wiki/Serine" title="Serine">serine</a> in it for flexibility as well as stretches of <a href="/wiki/Glutamate" class="mw-redirect" title="Glutamate">glutamate</a> and <a href="/wiki/Lysine" title="Lysine">lysine</a> for added <a href="/wiki/Solubility" title="Solubility">solubility</a>.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">&#91;18&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Transmembrane_domain">Transmembrane domain</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=6" title="Edit section: Transmembrane domain">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/Transmembrane_domain" title="Transmembrane domain">transmembrane domain</a> is a <a href="/wiki/Hydrophobic" class="mw-redirect" title="Hydrophobic">hydrophobic</a> <a href="/wiki/Alpha_helix" title="Alpha helix">alpha helix</a> that spans the membrane. The transmembrane domain is essential for the stability of the receptor as a whole. At present, the <a href="/wiki/CD28" title="CD28">CD28</a> transmembrane domain is the most stable of the domains.
</p><p>Generally, the transmembrane domain from the most membrane proximal component of the endodomain is used. Using the <a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3-zeta</a> transmembrane domain may result in incorporation of the artificial <a href="/wiki/T-cell_receptor" title="T-cell receptor">TCR</a> into the native TCR, a factor that is dependent on the presence of the native <a href="/wiki/CD3-zeta" class="mw-redirect" title="CD3-zeta">CD3-zeta</a> transmembrane charged <a href="/wiki/Aspartic_acid" title="Aspartic acid">aspartic acid</a> residue.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup> Different transmembrane domains result in different receptor stability. The <a href="/wiki/CD28" title="CD28">CD28</a> transmembrane domain results in a highly expressed, stable receptor.
</p>
<h3><span class="mw-headline" id="Endodomain">Endodomain</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=7" title="Edit section: Endodomain">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>This is the functional end of the receptor. After antigen recognition, receptors cluster and a signal is transmitted to the cell.<sup id="cite_ref-:3_16-1" class="reference"><a href="#cite_note-:3-16">&#91;16&#93;</a></sup> The most commonly used endodomain component is <a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a>-zeta which contains 3 <a href="/wiki/Immunoreceptor_tyrosine-based_activation_motif" title="Immunoreceptor tyrosine-based activation motif">ITAMs</a>. This transmits an activation signal to the T cell after the antigen is bound. CD3-zeta may not provide a fully competent activation signal and co-stimulatory signaling is needed. For example, chimeric <a href="/wiki/CD28" title="CD28">CD28</a> and <a href="/wiki/OX40" class="mw-redirect" title="OX40">OX40</a> can be used with CD3-Zeta to transmit a proliferative/survival signal or all three can be used together.
</p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=8" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Depiction_of_3_generations_of_CARs.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/ae/Depiction_of_3_generations_of_CARs.jpg/220px-Depiction_of_3_generations_of_CARs.jpg" decoding="async" width="220" height="142" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/ae/Depiction_of_3_generations_of_CARs.jpg/330px-Depiction_of_3_generations_of_CARs.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/ae/Depiction_of_3_generations_of_CARs.jpg/440px-Depiction_of_3_generations_of_CARs.jpg 2x" data-file-width="627" data-file-height="405" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Depiction_of_3_generations_of_CARs.jpg" class="internal" title="Enlarge"></a></div>Depiction of first, second, and third generation chimeric antigen receptors with the scFv segments in green and the various TCR signalling components in red, blue and yellow.<sup id="cite_ref-jcancer_20-0" class="reference"><a href="#cite_note-jcancer-20">&#91;20&#93;</a></sup></div></div></div>
<p>First generation CARs were developed in 1989 by <a href="/wiki/Gideon_Gross" title="Gideon Gross">Gideon Gross</a> and <a href="/wiki/Zelig_Eshhar" title="Zelig Eshhar">Zelig Eshhar</a><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup><sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup> at <a href="/wiki/Weizmann_Institute" class="mw-redirect" title="Weizmann Institute">Weizmann Institute</a>, Israel.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup> The first generation of CARs are composed of an extracellular binding domain, a hinge region, a transmembrane domain, and one or more intracellular signaling domains.<sup id="cite_ref-Hartmann_4-1" class="reference"><a href="#cite_note-Hartmann-4">&#91;4&#93;</a></sup> Extracellular binding domain contains single‐chain variable fragments (scFvs) derived from tumor antigen‐reactive antibodies and usually have high specificity to tumor antigen.<sup id="cite_ref-Hartmann_4-2" class="reference"><a href="#cite_note-Hartmann-4">&#91;4&#93;</a></sup> All CARs harbor the CD3ζ chain domain as the intracellular signaling domain, which is the primary transmitter of signals. Second generation CARs also contain co‐stimulatory domains, like CD28 and/or 4‐1BB. The involvement of these intracellular signaling domains improve T cell proliferation, cytokine secretion, resistance to apoptosis, and in vivo persistence.<sup id="cite_ref-Hartmann_4-3" class="reference"><a href="#cite_note-Hartmann-4">&#91;4&#93;</a></sup> Besides co-stimulatory domains, the third‐generation CARs combine multiple signaling domains, such as CD3z-CD28-41BB or CD3z-CD28-OX40, to augment T cell activity. Preclinical data shows the third-generation CARs exhibit improved effector functions and in vivo persistence as compared to second‐generation CARs.<sup id="cite_ref-Hartmann_4-4" class="reference"><a href="#cite_note-Hartmann-4">&#91;4&#93;</a></sup> Recently, the fourth‐generation CARs (also known as TRUCKs or armored CARs), combine the expression of a second‐generation CAR with factors that enhance anti‐tumoral activity (e.g., cytokines, co‐stimulatory ligands).<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup>
</p><p>The evolution of CAR therapy is an excellent example of the application of basic research to the clinic. The <a href="/wiki/Phosphoinositide_3-kinase" title="Phosphoinositide 3-kinase">PI3K</a> binding site used was identified in co-receptor CD28,<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup> while the ITAM motifs were identified as a target of the CD4- and CD8-p56lck complexes.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup>
</p><p>The introduction of Strep-tag II sequence (an eight-residue minimal peptide sequence (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) that exhibits intrinsic affinity toward <a href="/wiki/Streptavidin" title="Streptavidin">streptavidin</a><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>) into specific sites in synthetic CARs or natural T-cell receptors provides engineered T cells with an identification marker for rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function and a functional element for selective antibody-coated, microbead-driven, large-scale expansion.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup><sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup> Strep-tag can be used to stimulate the engineered cells, causing them to grow rapidly. Using an antibody that binds the Strep-tag, the engineered cells can be expanded by 200-fold. Unlike existing methods this technology stimulates only cancer-specific T cells.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (December 2017)">citation needed</span></a></i>&#93;</sup>
</p>
<h3><span class="mw-headline" id="Smart_T_cell">Smart T cell</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=9" title="Edit section: Smart T cell">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Combined with exogenous molecules, some synthetic control devices have been implemented on CAR-T cells and alter the cell activity. Smart T cell is engineered with suicide gene or other synthetic control panels to precisely control therapeutic function over the timing and dosage, there by alleviating cytotoxicity.<sup id="cite_ref-Zhang_30-0" class="reference"><a href="#cite_note-Zhang-30">&#91;30&#93;</a></sup> Several strategies to improve safety and efficacy of CAR-T cells are:
</p><p><b>Suicide gene engineering:</b> engineered T cells are incorporated with suicide genes, which can be activated by extracellular molecule and then induce T cell apoptosis. Herpes simplex virus <a href="/wiki/Thymidine_kinase" title="Thymidine kinase">thymidine kinase</a> (HSV-TK) and inducible <a href="/wiki/Caspase" title="Caspase">caspase 9</a> (iCas9) are two types suicide genes have been integrated into CAR-T cells.<sup id="cite_ref-Zhang_30-1" class="reference"><a href="#cite_note-Zhang-30">&#91;30&#93;</a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup><sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup> In iCas9 system, the suicide gene is composed of the sequence of the mutated FK506-binding protein with high specificity to a small-molecule, AP1903 and a gene encoding human caspase 9 switch. When the release of cytokines by CAR-T cells becomes more pronounced than basic levels, the iCas9 can be dimerized and lead to rapid apoptosis of T cells. Although both suicide genes demonstrate a noticeable function of as a safety switch in clinical trials for cellular therapies, some hinder defects limit the application of this strategy. HSV-TK is derived from virus and may be immunogenic to humans.<sup id="cite_ref-Zhang_30-2" class="reference"><a href="#cite_note-Zhang-30">&#91;30&#93;</a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup> The suicide gene strategies may not act quickly enough to eliminate off-tumor cytotoxicity as well.
</p><p><b>Dual-antigen receptor:</b> T cells are engineered to express two tumor-associated antigen receptors at the same time. The dual-antigen receptor of engineered T cell module has been reported to have less intense side effects.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">&#91;34&#93;</a></sup> The activation of CAR-T cell via <a href="/wiki/T-cell_receptor" title="T-cell receptor">TCR</a>-CD3ζ signal transduction pathway is transient and a complementary signal pathway provided by co-stimulatory molecules on antigen presenting cells promotes survival of modified-T cell can ability in controlling tumor.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup> An in vivo study in mice shows the dual-receptor T cells effectively eradicated prostate cancer and achieved complete long-term survival.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup>
</p><p><b>ON-switch:</b> ON-switch CAR-T cell split synthetic receptors into two parts: the first part mainly contains an antigen binding domain towards and the other part features two different downstream signaling elements (e.g. CD3ζ and 4-1BB). Upon the presence of an exogenous molecule (rapamycin analogs for example), two physically separated signaling elements fuse together and CAR-T cells exert therapeutic functions.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">&#91;37&#93;</a></sup> In this mechanism, the engineered T cell shows therapeutic function only in the presence of both tumor antigen and a benign exogenous molecule.
</p><p><b>Bifunctional molecules as switches:</b> The bispecific antibodies are developed as an efficacious bridge to target cytotoxic T cells to cancer cells and causes localized T cell activation. In this strategy, the bispecific antibody targets CD3 molecule of T cell and tumor-associated antigen presented on cancer cell surface.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">&#91;38&#93;</a></sup> The anti-CD20/CD3 bispecific molecule shows high specificity to both malignant B cells and cancer cells in mice.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">&#91;39&#93;</a></sup> <a href="/wiki/Fluorescein_isothiocyanate" title="Fluorescein isothiocyanate">FITC</a> is another bifunctional molecule used in this strategy. <a href="/wiki/Fluorescein_isothiocyanate" title="Fluorescein isothiocyanate">FITC</a> can redirect and regulate the activity of the <a href="/wiki/Fluorescein_isothiocyanate" title="Fluorescein isothiocyanate">FITC</a>-specific CAR-T cells toward tumor cells with folate receptors.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40">&#91;40&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="SMDC_adaptor_technology">SMDC adaptor technology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=10" title="Edit section: SMDC adaptor technology">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>SMDCs (small molecule drug conjugates) platform in immuno-oncology is a novel (currently experimental) approach that makes possible the engineering of a single universal CAR T cell, which binds with extraordinarily high affinity to a benign molecule designated as <a href="/wiki/Fluorescein_isothiocyanate" title="Fluorescein isothiocyanate">FITC</a>. These cells are then used to treat various cancer types when co-administered with bispecific SMDC adaptor molecules. These unique bispecific adaptors are constructed with a <a href="/wiki/Fluorescein_isothiocyanate" title="Fluorescein isothiocyanate">FITC molecule</a> and a tumor-homing molecule to precisely bridge the universal CAR T cell with the cancer cells, which causes localized T cell activation. Anti-tumor activity in mice is induced only when both the universal CAR T cells plus the correct antigen-specific adaptor molecules are present. Anti-tumor activity and toxicity can be controlled by adjusting the administered adaptor molecule dosing. Treatment of antigenically heterogeneous tumors can be achieved by administration of a mixture of the desired antigen-specific adaptors. Thus, several challenges of current CAR T cell therapies, such as: 
</p>
<ul><li>the inability to control the rate of cytokine release and tumor lysis</li>
<li>the absence of an “off switch” that can terminate cytotoxic activity when tumor eradication is complete</li>
<li>a requirement to generate a different CAR T cell for each unique tumor antigen</li></ul>
<p>may be solved or mitigated using this approach.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">&#91;41&#93;</a></sup><sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup><sup id="cite_ref-43" class="reference"><a href="#cite_note-43">&#91;43&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Clinical_studies">Clinical studies</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=11" title="Edit section: Clinical studies">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>As of August 2017, there were around 200 clinical trials happening globally involving CAR-T cells.<sup id="cite_ref-Hartmann2017_10-2" class="reference"><a href="#cite_note-Hartmann2017-10">&#91;10&#93;</a></sup> Around 65% of those trials targeted blood cancers, and 80% of them involved CD19 CAR-T cells targeting B-cell cancers.<sup id="cite_ref-Hartmann2017_10-3" class="reference"><a href="#cite_note-Hartmann2017-10">&#91;10&#93;</a></sup>  In 2016, studies began to explore the viability of other antigens, such as CD20.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">&#91;44&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="FDA_approvals">FDA approvals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=12" title="Edit section: FDA approvals">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The first two FDA approved CAR-T therapies both target the <a href="/wiki/CD19" title="CD19">CD19</a> antigen, which is found on many types of B-cell cancers.<sup id="cite_ref-HO_45-0" class="reference"><a href="#cite_note-HO-45">&#91;45&#93;</a></sup> <a href="/wiki/Tisagenlecleucel" title="Tisagenlecleucel">Tisagenlecleucel</a> (Kymriah) is approved to treat relapsed/refractory B-cell precursor <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a> (ALL), while <a href="/wiki/Axicabtagene_ciloleucel" title="Axicabtagene ciloleucel">axicabtagene ciloleucel</a> (Yescarta) is approved to treat relapsed/refractory <a href="/wiki/Diffuse_large_B-cell_lymphoma" title="Diffuse large B-cell lymphoma">diffuse large B-cell lymphoma</a> (DLBCL).<sup id="cite_ref-HO_45-1" class="reference"><a href="#cite_note-HO-45">&#91;45&#93;</a></sup>
</p><p>Kymriah's clinical trial showed an 83% remission rate of all types of B-cell ALL after three months post treatment.<sup id="cite_ref-news_46-0" class="reference"><a href="#cite_note-news-46">&#91;46&#93;</a></sup> However, 49% of patients also suffered cytokine release syndrome (CRS), a serious side effect that has been responsible for several deaths in clinical trials run by Novartis’ competitors.<sup id="cite_ref-news_46-1" class="reference"><a href="#cite_note-news-46">&#91;46&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=13" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a href="/wiki/Gene_therapy" title="Gene therapy">Gene therapy</a></li></ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=14" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist" style="list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-newsweek-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-newsweek_1-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Fox, Maggie (July 12, 2017). <a rel="nofollow" class="external text" href="https://www.nbcnews.com/health/health-news/new-gene-therapy-cancer-offers-hope-those-no-options-left-n741326">"New Gene Therapy for Cancer Offers Hope to Those With No Options Left"</a>. <i>NBC News</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NBC+News&amp;rft.atitle=New+Gene+Therapy+for+Cancer+Offers+Hope+to+Those+With+No+Options+Left&amp;rft.date=2017-07-12&amp;rft.aulast=Fox&amp;rft.aufirst=Maggie&amp;rft_id=https%3A%2F%2Fwww.nbcnews.com%2Fhealth%2Fhealth-news%2Fnew-gene-therapy-cancer-offers-hope-those-no-options-left-n741326&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r879151008">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><cite class="citation journal">Srivastava S, Riddell SR (August 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4746114">"Engineering CAR-T cells: Design concepts"</a>. <i>Trends in Immunology</i>. <b>36</b> (8): 494–502. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.it.2015.06.004">10.1016/j.it.2015.06.004</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4746114">4746114</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26169254">26169254</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Trends+in+Immunology&amp;rft.atitle=Engineering+CAR-T+cells%3A+Design+concepts&amp;rft.volume=36&amp;rft.issue=8&amp;rft.pages=494-502&amp;rft.date=2015-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4746114&amp;rft_id=info%3Apmid%2F26169254&amp;rft_id=info%3Adoi%2F10.1016%2Fj.it.2015.06.004&amp;rft.aulast=Srivastava&amp;rft.aufirst=S&amp;rft.au=Riddell%2C+SR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4746114&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sadelain M, Brentjens R, Rivière I (April 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3667586">"The basic principles of chimeric antigen receptor design"</a>. <i>Cancer Discovery</i>. <b>3</b> (4): 388–98. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1158%2F2159-8290.CD-12-0548">10.1158/2159-8290.CD-12-0548</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3667586">3667586</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23550147">23550147</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Discovery&amp;rft.atitle=The+basic+principles+of+chimeric+antigen+receptor+design&amp;rft.volume=3&amp;rft.issue=4&amp;rft.pages=388-98&amp;rft.date=2013-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3667586&amp;rft_id=info%3Apmid%2F23550147&amp;rft_id=info%3Adoi%2F10.1158%2F2159-8290.CD-12-0548&amp;rft.aulast=Sadelain&amp;rft.aufirst=M&amp;rft.au=Brentjens%2C+R&amp;rft.au=Rivi%C3%A8re%2C+I&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3667586&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Hartmann-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hartmann_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hartmann_4-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Hartmann_4-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Hartmann_4-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Hartmann_4-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (2017). "Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts". <i>EMBO Molecular Medicine</i>. <b>9</b> (9): 1183–1197. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.15252%2Femmm.201607485">10.15252/emmm.201607485</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=EMBO+Molecular+Medicine&amp;rft.atitle=Clinical+development+of+CAR+T+cells-challenges+and+opportunities+in+translating+innovative+treatment+concepts.&amp;rft.volume=9&amp;rft.issue=9&amp;rft.pages=1183-1197&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.15252%2Femmm.201607485&amp;rft.aulast=Hartmann&amp;rft.aufirst=J&amp;rft.au=Sch%C3%BC%C3%9Fler-Lenz%2C+M&amp;rft.au=Bondanza%2C+A&amp;rft.au=Buchholz%2C+CJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><cite class="citation journal">Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, Wang B, Warnock GL, Dai LJ, Luo J (December 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4792550">"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy"</a>. <i>Oncotarget</i>. <b>6</b> (42): 44179–90. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.18632%2Foncotarget.6175">10.18632/oncotarget.6175</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4792550">4792550</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26496034">26496034</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncotarget&amp;rft.atitle=Therapeutic+potential+of+CAR-T+cell-derived+exosomes%3A+a+cell-free+modality+for+targeted+cancer+therapy&amp;rft.volume=6&amp;rft.issue=42&amp;rft.pages=44179-90&amp;rft.date=2015-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4792550&amp;rft_id=info%3Apmid%2F26496034&amp;rft_id=info%3Adoi%2F10.18632%2Foncotarget.6175&amp;rft.aulast=Tang&amp;rft.aufirst=XJ&amp;rft.au=Sun%2C+XY&amp;rft.au=Huang%2C+KM&amp;rft.au=Zhang%2C+L&amp;rft.au=Yang%2C+ZS&amp;rft.au=Zou%2C+DD&amp;rft.au=Wang%2C+B&amp;rft.au=Warnock%2C+GL&amp;rft.au=Dai%2C+LJ&amp;rft.au=Luo%2C+J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4792550&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation journal">Jacobson CA, Ritz J (November 2011). "Time to put the CAR-T before the horse". <i>Blood</i>. <b>118</b> (18): 4761–2. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1182%2Fblood-2011-09-376137">10.1182/blood-2011-09-376137</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22053170">22053170</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=Time+to+put+the+CAR-T+before+the+horse&amp;rft.volume=118&amp;rft.issue=18&amp;rft.pages=4761-2&amp;rft.date=2011-11&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2011-09-376137&amp;rft_id=info%3Apmid%2F22053170&amp;rft.aulast=Jacobson&amp;rft.aufirst=CA&amp;rft.au=Ritz%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation journal">Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M (2014-03-05). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4362340">"Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors"</a>. <i>Molecular Therapy. Methods &amp; Clinical Development</i>. <b>1</b>: 14001. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fmtm.2014.1">10.1038/mtm.2014.1</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4362340">4362340</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26015949">26015949</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Therapy.+Methods+%26+Clinical+Development&amp;rft.atitle=Allogeneic+lymphocyte-licensed+DCs+expand+T+cells+with+improved+antitumor+activity+and+resistance+to+oxidative+stress+and+immunosuppressive+factors&amp;rft.volume=1&amp;rft.pages=14001&amp;rft.date=2014-03-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4362340&amp;rft_id=info%3Apmid%2F26015949&amp;rft_id=info%3Adoi%2F10.1038%2Fmtm.2014.1&amp;rft.aulast=Jin&amp;rft.aufirst=C&amp;rft.au=Yu%2C+D&amp;rft.au=Hillerdal%2C+V&amp;rft.au=Wallgren%2C+A&amp;rft.au=Karlsson-Parra%2C+A&amp;rft.au=Essand%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4362340&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:0-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_8-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Makita S, Yoshimura K, Tobinai K (June 2017). "Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma". <i>Cancer Science</i>. <b>108</b> (6): 1109–1118. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1111%2Fcas.13239">10.1111/cas.13239</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28301076">28301076</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Science&amp;rft.atitle=Clinical+development+of+anti-CD19+chimeric+antigen+receptor+T-cell+therapy+for+B-cell+non-Hodgkin+lymphoma&amp;rft.volume=108&amp;rft.issue=6&amp;rft.pages=1109-1118&amp;rft.date=2017-06&amp;rft_id=info%3Adoi%2F10.1111%2Fcas.13239&amp;rft_id=info%3Apmid%2F28301076&amp;rft.aulast=Makita&amp;rft.aufirst=S&amp;rft.au=Yoshimura%2C+K&amp;rft.au=Tobinai%2C+K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><cite class="citation journal">Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D (July 2016). <a rel="nofollow" class="external text" href="http://embomolmed.embopress.org/content/8/7/702">"Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer"</a>. <i>EMBO Molecular Medicine</i>. <b>8</b> (7): 702–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.15252%2Femmm.201505869">10.15252/emmm.201505869</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27189167">27189167</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=EMBO+Molecular+Medicine&amp;rft.atitle=Safe+engineering+of+CAR+T+cells+for+adoptive+cell+therapy+of+cancer+using+long-term+episomal+gene+transfer&amp;rft.volume=8&amp;rft.issue=7&amp;rft.pages=702-11&amp;rft.date=2016-07&amp;rft_id=info%3Adoi%2F10.15252%2Femmm.201505869&amp;rft_id=info%3Apmid%2F27189167&amp;rft.aulast=Jin&amp;rft.aufirst=C&amp;rft.au=Fotaki%2C+G&amp;rft.au=Ramachandran%2C+M&amp;rft.au=Nilsson%2C+B&amp;rft.au=Essand%2C+M&amp;rft.au=Yu%2C+D&amp;rft_id=http%3A%2F%2Fembomolmed.embopress.org%2Fcontent%2F8%2F7%2F702&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Hartmann2017-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hartmann2017_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hartmann2017_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Hartmann2017_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Hartmann2017_10-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (September 2017). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5582407">"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts"</a>. <i>EMBO Molecular Medicine</i>. <b>9</b> (9): 1183–1197. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.15252%2Femmm.201607485">10.15252/emmm.201607485</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5582407">5582407</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28765140">28765140</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=EMBO+Molecular+Medicine&amp;rft.atitle=Clinical+development+of+CAR+T+cells-challenges+and+opportunities+in+translating+innovative+treatment+concepts&amp;rft.volume=9&amp;rft.issue=9&amp;rft.pages=1183-1197&amp;rft.date=2017-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5582407&amp;rft_id=info%3Apmid%2F28765140&amp;rft_id=info%3Adoi%2F10.15252%2Femmm.201607485&amp;rft.aulast=Hartmann&amp;rft.aufirst=J&amp;rft.au=Sch%C3%BC%C3%9Fler-Lenz%2C+M&amp;rft.au=Bondanza%2C+A&amp;rft.au=Buchholz%2C+CJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5582407&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><cite class="citation journal">Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (December 2006). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1773008">"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?"</a>. <i>Nature Clinical Practice Oncology</i>. <b>3</b> (12): 668–81. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fncponc0666">10.1038/ncponc0666</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1773008">1773008</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17139318">17139318</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Clinical+Practice+Oncology&amp;rft.atitle=Increased+intensity+lymphodepletion+and+adoptive+immunotherapy--how+far+can+we+go%3F&amp;rft.volume=3&amp;rft.issue=12&amp;rft.pages=668-81&amp;rft.date=2006-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1773008&amp;rft_id=info%3Apmid%2F17139318&amp;rft_id=info%3Adoi%2F10.1038%2Fncponc0666&amp;rft.aulast=Muranski&amp;rft.aufirst=P&amp;rft.au=Boni%2C+A&amp;rft.au=Wrzesinski%2C+C&amp;rft.au=Citrin%2C+DE&amp;rft.au=Rosenberg%2C+SA&amp;rft.au=Childs%2C+R&amp;rft.au=Restifo%2C+NP&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1773008&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><cite class="citation journal">Breslin S (February 2007). "Cytokine-release syndrome: overview and nursing implications". <i><a href="/wiki/Clinical_Journal_of_Oncology_Nursing" title="Clinical Journal of Oncology Nursing">Clinical Journal of Oncology Nursing</a></i>. <b>11</b> (1 Suppl): 37–42. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1188%2F07.CJON.S1.37-42">10.1188/07.CJON.S1.37-42</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17471824">17471824</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Journal+of+Oncology+Nursing.&amp;rft.atitle=Cytokine-release+syndrome%3A+overview+and+nursing+implications&amp;rft.volume=11&amp;rft.issue=1+Suppl&amp;rft.pages=37-42&amp;rft.date=2007-02&amp;rft_id=info%3Adoi%2F10.1188%2F07.CJON.S1.37-42&amp;rft_id=info%3Apmid%2F17471824&amp;rft.aulast=Breslin&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:2-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-:2_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:2_13-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265">"Toxicity and management in CAR-T cell therapy"</a>. <i>Molecular Therapy Oncolytics</i>. <b>3</b>: 16011. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fmto.2016.11">10.1038/mto.2016.11</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265">5008265</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27626062">27626062</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Therapy+Oncolytics&amp;rft.atitle=Toxicity+and+management+in+CAR-T+cell+therapy&amp;rft.volume=3&amp;rft.pages=16011&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5008265&amp;rft_id=info%3Apmid%2F27626062&amp;rft_id=info%3Adoi%2F10.1038%2Fmto.2016.11&amp;rft.aulast=Bonifant&amp;rft.aufirst=CL&amp;rft.au=Jackson%2C+HJ&amp;rft.au=Brentjens%2C+RJ&amp;rft.au=Curran%2C+KJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5008265&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://clinicaltrials.gov/ct2/show/NCT02535364">"Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)"</a>. <i>ClinicalTrials.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-02-21</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ClinicalTrials.gov&amp;rft.atitle=Study+Evaluating+the+Efficacy+and+Safety+of+JCAR015+in+Adult+B-cell+Acute+Lymphoblastic+Leukemia+%28B-ALL%29&amp;rft_id=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02535364&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation journal">Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (June 2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4887159">"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients"</a>. <i>The Journal of Clinical Investigation</i>. <b>126</b> (6): 2123–38. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1172%2FJCI85309">10.1172/JCI85309</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4887159">4887159</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27111235">27111235</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Clinical+Investigation&amp;rft.atitle=CD19+CAR-T+cells+of+defined+CD4%2B%3ACD8%2B+composition+in+adult+B+cell+ALL+patients&amp;rft.volume=126&amp;rft.issue=6&amp;rft.pages=2123-38&amp;rft.date=2016-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4887159&amp;rft_id=info%3Apmid%2F27111235&amp;rft_id=info%3Adoi%2F10.1172%2FJCI85309&amp;rft.aulast=Turtle&amp;rft.aufirst=CJ&amp;rft.au=Hanafi%2C+LA&amp;rft.au=Berger%2C+C&amp;rft.au=Gooley%2C+TA&amp;rft.au=Cherian%2C+S&amp;rft.au=Hudecek%2C+M&amp;rft.au=Sommermeyer%2C+D&amp;rft.au=Melville%2C+K&amp;rft.au=Pender%2C+B&amp;rft.au=Budiarto%2C+TM&amp;rft.au=Robinson%2C+E&amp;rft.au=Steevens%2C+NN&amp;rft.au=Chaney%2C+C&amp;rft.au=Soma%2C+L&amp;rft.au=Chen%2C+X&amp;rft.au=Yeung%2C+C&amp;rft.au=Wood%2C+B&amp;rft.au=Li%2C+D&amp;rft.au=Cao%2C+J&amp;rft.au=Heimfeld%2C+S&amp;rft.au=Jensen%2C+MC&amp;rft.au=Riddell%2C+SR&amp;rft.au=Maloney%2C+DG&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4887159&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:3-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-:3_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:3_16-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Zhang C, Liu J, Zhong JF, Zhang X (2017-06-24). <a rel="nofollow" class="external text" href="https://doi.org/10.1186/s40364-017-0102-y">"Engineering CAR-T cells"</a>. <i>Biomarker Research</i>. <b>5</b>: 22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1186%2Fs40364-017-0102-y">10.1186/s40364-017-0102-y</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28652918">28652918</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Biomarker+Research&amp;rft.atitle=Engineering+CAR-T+cells&amp;rft.volume=5&amp;rft.pages=22&amp;rft.date=2017-06-24&amp;rft_id=info%3Adoi%2F10.1186%2Fs40364-017-0102-y&amp;rft_id=info%3Apmid%2F28652918&amp;rft.aulast=Zhang&amp;rft.aufirst=C&amp;rft.au=Liu%2C+J&amp;rft.au=Zhong%2C+JF&amp;rft.au=Zhang%2C+X&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1186%2Fs40364-017-0102-y&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation journal">Monnier PP, Vigouroux RJ, Tassew NG (April 2013). <a rel="nofollow" class="external text" href="http://www.mdpi.com/2073-4468/2/2/193">"In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments"</a>. <i>Antibodies</i>. <b>2</b> (2): 193–208. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.3390%2Fantib2020193">10.3390/antib2020193</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antibodies&amp;rft.atitle=In+Vivo+Applications+of+Single+Chain+Fv+%28Variable+Domain%29+%28scFv%29+Fragments&amp;rft.volume=2&amp;rft.issue=2&amp;rft.pages=193-208&amp;rft.date=2013-04&amp;rft_id=info%3Adoi%2F10.3390%2Fantib2020193&amp;rft.aulast=Monnier&amp;rft.aufirst=Philippe+P.&amp;rft.au=Vigouroux%2C+Robin+J.&amp;rft.au=Tassew%2C+Nardos+G.&amp;rft_id=http%3A%2F%2Fwww.mdpi.com%2F2073-4468%2F2%2F2%2F193&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation journal">Baldo BA (May 2015). "Chimeric fusion proteins used for therapy: indications, mechanisms, and safety". <i>Drug Safety</i>. <b>38</b> (5): 455–79. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1007%2Fs40264-015-0285-9">10.1007/s40264-015-0285-9</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25832756">25832756</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Safety&amp;rft.atitle=Chimeric+fusion+proteins+used+for+therapy%3A+indications%2C+mechanisms%2C+and+safety&amp;rft.volume=38&amp;rft.issue=5&amp;rft.pages=455-79&amp;rft.date=2015-05&amp;rft_id=info%3Adoi%2F10.1007%2Fs40264-015-0285-9&amp;rft_id=info%3Apmid%2F25832756&amp;rft.aulast=Baldo&amp;rft.aufirst=BA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><cite class="citation journal">Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE (June 2010). "The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex". <i>Journal of Immunology</i>. <b>184</b> (12): 6938–49. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.4049%2Fjimmunol.0901766">10.4049/jimmunol.0901766</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20483753">20483753</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Immunology&amp;rft.atitle=The+optimal+antigen+response+of+chimeric+antigen+receptors+harboring+the+CD3zeta+transmembrane+domain+is+dependent+upon+incorporation+of+the+receptor+into+the+endogenous+TCR%2FCD3+complex&amp;rft.volume=184&amp;rft.issue=12&amp;rft.pages=6938-49&amp;rft.date=2010-06&amp;rft_id=info%3Adoi%2F10.4049%2Fjimmunol.0901766&amp;rft_id=info%3Apmid%2F20483753&amp;rft.aulast=Bridgeman&amp;rft.aufirst=JS&amp;rft.au=Hawkins%2C+RE&amp;rft.au=Bagley%2C+S&amp;rft.au=Blaylock%2C+M&amp;rft.au=Holland%2C+M&amp;rft.au=Gilham%2C+DE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-jcancer-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-jcancer_20-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Casucci M, Bondanza A (2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3133962">"Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes"</a>. <i>Journal of Cancer</i>. <b>2</b>: 378–82. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.7150%2Fjca.2.378">10.7150/jca.2.378</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3133962">3133962</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21750689">21750689</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Cancer&amp;rft.atitle=Suicide+gene+therapy+to+increase+the+safety+of+chimeric+antigen+receptor-redirected+T+lymphocytes&amp;rft.volume=2&amp;rft.pages=378-82&amp;rft.date=2011&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3133962&amp;rft_id=info%3Apmid%2F21750689&amp;rft_id=info%3Adoi%2F10.7150%2Fjca.2.378&amp;rft.aulast=Casucci&amp;rft.aufirst=M&amp;rft.au=Bondanza%2C+A&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3133962&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation journal">Gross G, Gorochov G, Waks T, Eshhar Z (February 1989). "Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity". <i>Transplantation Proceedings</i>. <b>21</b> (1 Pt 1): 127–30. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2784887">2784887</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Transplantation+Proceedings&amp;rft.atitle=Generation+of+effector+T+cells+expressing+chimeric+T+cell+receptor+with+antibody+type-specificity&amp;rft.volume=21&amp;rft.issue=1+Pt+1&amp;rft.pages=127-30&amp;rft.date=1989-02&amp;rft_id=info%3Apmid%2F2784887&amp;rft.aulast=Gross&amp;rft.aufirst=G&amp;rft.au=Gorochov%2C+G&amp;rft.au=Waks%2C+T&amp;rft.au=Eshhar%2C+Z&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rosenbaum L (October 2017). "Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy". <i>The New England Journal of Medicine</i>. <b>377</b> (14): 1313–1315. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1056%2FNEJMp1711886">10.1056/NEJMp1711886</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28902570">28902570</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Tragedy%2C+Perseverance%2C+and+Chance+-+The+Story+of+CAR-T+Therapy&amp;rft.volume=377&amp;rft.issue=14&amp;rft.pages=1313-1315&amp;rft.date=2017-10&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMp1711886&amp;rft_id=info%3Apmid%2F28902570&amp;rft.aulast=Rosenbaum&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation journal">Gross G, Waks T, Eshhar Z (December 1989). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC298636">"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>86</b> (24): 10024–8. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/1989PNAS...8610024G">1989PNAS...8610024G</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1073%2Fpnas.86.24.10024">10.1073/pnas.86.24.10024</a>. <a href="/wiki/JSTOR" title="JSTOR">JSTOR</a>&#160;<a rel="nofollow" class="external text" href="//www.jstor.org/stable/34790">34790</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC298636">298636</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2513569">2513569</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;rft.atitle=Expression+of+immunoglobulin-T-cell+receptor+chimeric+molecules+as+functional+receptors+with+antibody-type+specificity&amp;rft.volume=86&amp;rft.issue=24&amp;rft.pages=10024-8&amp;rft.date=1989-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC298636&amp;rft_id=%2F%2Fwww.jstor.org%2Fstable%2F34790&amp;rft_id=info%3Abibcode%2F1989PNAS...8610024G&amp;rft_id=info%3Apmid%2F2513569&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.86.24.10024&amp;rft.aulast=Gross&amp;rft.aufirst=G&amp;rft.au=Waks%2C+T&amp;rft.au=Eshhar%2C+Z&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC298636&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation journal">Chmielewski M, Abken H (2015). "TRUCKs: the fourth generation of CARs". <i>Expert Opin Biol</i>. <b>15</b> (8): 1145–1154. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1517%2F14712598.2015.1046430">10.1517/14712598.2015.1046430</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opin+Biol&amp;rft.atitle=TRUCKs%3A+the+fourth+generation+of+CARs.&amp;rft.volume=15&amp;rft.issue=8&amp;rft.pages=1145-1154&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1517%2F14712598.2015.1046430&amp;rft.aulast=Chmielewski&amp;rft.aufirst=M&amp;rft.au=Abken%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rudd CE, Schneider H (July 2003). "Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling". <i>Nature Reviews. Immunology</i>. <b>3</b> (7): 544–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnri1131">10.1038/nri1131</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12876557">12876557</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Immunology&amp;rft.atitle=Unifying+concepts+in+CD28%2C+ICOS+and+CTLA4+co-receptor+signalling&amp;rft.volume=3&amp;rft.issue=7&amp;rft.pages=544-56&amp;rft.date=2003-07&amp;rft_id=info%3Adoi%2F10.1038%2Fnri1131&amp;rft_id=info%3Apmid%2F12876557&amp;rft.aulast=Rudd&amp;rft.aufirst=CE&amp;rft.au=Schneider%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rudd CE (January 1999). "Adaptors and molecular scaffolds in immune cell signaling". <i>Cell</i>. <b>96</b> (1): 5–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2FS0092-8674%2800%2980953-8">10.1016/S0092-8674(00)80953-8</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9989491">9989491</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cell&amp;rft.atitle=Adaptors+and+molecular+scaffolds+in+immune+cell+signaling&amp;rft.volume=96&amp;rft.issue=1&amp;rft.pages=5-8&amp;rft.date=1999-01&amp;rft_id=info%3Adoi%2F10.1016%2FS0092-8674%2800%2980953-8&amp;rft_id=info%3Apmid%2F9989491&amp;rft.aulast=Rudd&amp;rft.aufirst=CE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation journal">Schmidt TG, Skerra A (2007). "The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins". <i>Nature Protocols</i>. <b>2</b> (6): 1528–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnprot.2007.209">10.1038/nprot.2007.209</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17571060">17571060</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Protocols&amp;rft.atitle=The+Strep-tag+system+for+one-step+purification+and+high-affinity+detection+or+capturing+of+proteins&amp;rft.volume=2&amp;rft.issue=6&amp;rft.pages=1528-35&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1038%2Fnprot.2007.209&amp;rft_id=info%3Apmid%2F17571060&amp;rft.aulast=Schmidt&amp;rft.aufirst=TG&amp;rft.au=Skerra%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation journal">Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR (April 2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4940167">"Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy"</a>. <i>Nature Biotechnology</i>. <b>34</b> (4): 430–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnbt.3461">10.1038/nbt.3461</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4940167">4940167</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26900664">26900664</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biotechnology&amp;rft.atitle=Inclusion+of+Strep-tag+II+in+design+of+antigen+receptors+for+T-cell+immunotherapy&amp;rft.volume=34&amp;rft.issue=4&amp;rft.pages=430-4&amp;rft.date=2016-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4940167&amp;rft_id=info%3Apmid%2F26900664&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt.3461&amp;rft.aulast=Liu&amp;rft.aufirst=L&amp;rft.au=Sommermeyer%2C+D&amp;rft.au=Cabanov%2C+A&amp;rft.au=Kosasih%2C+P&amp;rft.au=Hill%2C+T&amp;rft.au=Riddell%2C+SR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4940167&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.fredhutch.org/en/news/center-news/2016/02/crafting-a-better-t-cell-for-immunotherapy.html">Crafting a better T cell for immunotherapy</a>. New technology aims to reduce patients’ waiting time, increase potency of T-cell therapy</span>
</li>
<li id="cite_note-Zhang-30"><span class="mw-cite-backlink">^ <a href="#cite_ref-Zhang_30-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Zhang_30-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Zhang_30-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Zhang E, Xu H (2017). "A new insight in chimeric antigen receptor‐engineered T cells for cancer immunotherapy". <i>Hematol Oncol</i>. <b>10</b> (1). <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1186%2Fs13045-016-0379-6">10.1186/s13045-016-0379-6</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hematol+Oncol&amp;rft.atitle=A+new+insight+in+chimeric+antigen+receptor%E2%80%90engineered+T+cells+for+cancer+immunotherapy.&amp;rft.volume=10&amp;rft.issue=1&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1186%2Fs13045-016-0379-6&amp;rft.aulast=Zhang&amp;rft.aufirst=E&amp;rft.au=Xu%2C+H&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation journal">Bonini C, Ferrari G (1997). "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia". <i>Science</i>. <b>276</b>: 1719–1724. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscience.276.5319.1719">10.1126/science.276.5319.1719</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=HSV-TK+gene+transfer+into+donor+lymphocytes+for+control+of+allogeneic+graft-versus-leukemia.&amp;rft.volume=276&amp;rft.pages=1719-1724&amp;rft.date=1997&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.276.5319.1719&amp;rft.aulast=Bonini&amp;rft.aufirst=C&amp;rft.au=Ferrari%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><cite class="citation journal">Quintarelli C, Vera JF (2007). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2018664">"Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes"</a>. <i>Blood</i>. <b>110</b>: 2793–2802. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1182%2Fblood-2007-02-072843">10.1182/blood-2007-02-072843</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2018664">2018664</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=Co-expression+of+cytokine+and+suicide+genes+to+enhance+the+activity+and+safety+of+tumor-specific+cytotoxic+T+lymphocytes.&amp;rft.volume=110&amp;rft.pages=2793-2802&amp;rft.date=2007&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2018664&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2007-02-072843&amp;rft.aulast=Quintarelli&amp;rft.aufirst=C&amp;rft.au=Vera%2C+JF&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2018664&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation journal">Riddell SR, Elliott M (1996). "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients". <i>Nat Med</i>. <b>2</b>: 216–223. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnm0296-216">10.1038/nm0296-216</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Med&amp;rft.atitle=T-cell+mediated+rejection+of+gene-modified+HIV-specific+cytotoxic+T+lymphocytes+in+HIV-infected+patients.&amp;rft.volume=2&amp;rft.pages=216-223&amp;rft.date=1996&amp;rft_id=info%3Adoi%2F10.1038%2Fnm0296-216&amp;rft.aulast=Riddell&amp;rft.aufirst=SR&amp;rft.au=Elliott%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><cite class="citation journal">Maher J, Brentjens RJ (2002). "<a href="/wiki/T-cell_receptor" title="T-cell receptor">TCR</a>". <i>Nat Biotechnol</i>. <b>20</b>: 70–75. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnbt0102-70">10.1038/nbt0102-70</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat+Biotechnol&amp;rft.atitle=Human+T-lymphocyte+cytotoxicity+and+proliferation+directed+by+a+single+chimeric+TCR%CE%B6%2FCD28+receptor.&amp;rft.volume=20&amp;rft.pages=70-75&amp;rft.date=2002&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0102-70&amp;rft.aulast=Maher&amp;rft.aufirst=J&amp;rft.au=Brentjens%2C+RJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation journal">Liu JC, Voisin V (2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3326451">"Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+: ERα−breast cancer"</a>. <i>PNAS</i>. <b>109</b>: 5832–5837. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2012PNAS..109.5832L">2012PNAS..109.5832L</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1073%2Fpnas.1201105109">10.1073/pnas.1201105109</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3326451">3326451</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PNAS&amp;rft.atitle=Seventeen-gene+signature+from+enriched+Her2%2FNeu+mammary+tumor-initiating+cells+predicts+clinical+outcome+for+human+HER2%2B%3A+ER%CE%B1%E2%88%92breast+cancer.&amp;rft.volume=109&amp;rft.pages=5832-5837&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3326451&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.1201105109&amp;rft_id=info%3Abibcode%2F2012PNAS..109.5832L&amp;rft.aulast=Liu&amp;rft.aufirst=JC&amp;rft.au=Voisin%2C+V&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3326451&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wilkie S, van Schalkwyk MC (2012). "Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling". <i>Clin Immunol</i>. <b>32</b>: 1059–1070. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1007%2Fs10875-012-9689-9">10.1007/s10875-012-9689-9</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin+Immunol&amp;rft.atitle=Dual+targeting+of+ErbB2+and+MUC1+in+breast+cancer+using+chimeric+antigen+receptors+engineered+to+provide+complementary+signaling.&amp;rft.volume=32&amp;rft.pages=1059-1070&amp;rft.date=2012&amp;rft_id=info%3Adoi%2F10.1007%2Fs10875-012-9689-9&amp;rft.aulast=Wilkie&amp;rft.aufirst=S&amp;rft.au=van+Schalkwyk%2C+MC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wu CY (2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4721629">"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor"</a>. <i>Science</i>. <b>350</b>: aab4077. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2015Sci...350.4077W">2015Sci...350.4077W</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscience.aab4077">10.1126/science.aab4077</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4721629">4721629</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=Remote+control+of+therapeutic+T+cells+through+a+small+molecule-gated+chimeric+receptor.&amp;rft.volume=350&amp;rft.pages=aab4077&amp;rft.date=2015&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4721629&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.aab4077&amp;rft_id=info%3Abibcode%2F2015Sci...350.4077W&amp;rft.aulast=Wu&amp;rft.aufirst=CY&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4721629&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite class="citation journal">Frankel SR (2013). "Targeting T cells to tumor cells using bispecific antibodies". <i>Curr Opin Chem Biol</i>. <b>17</b>: 385–392. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.cbpa.2013.03.029">10.1016/j.cbpa.2013.03.029</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr+Opin+Chem+Biol&amp;rft.atitle=Targeting+T+cells+to+tumor+cells+using+bispecific+antibodies.&amp;rft.volume=17&amp;rft.pages=385-392&amp;rft.date=2013&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cbpa.2013.03.029&amp;rft.aulast=Frankel&amp;rft.aufirst=SR&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sun LL (2015). "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies". <i>Sci Transl Med</i>. <b>7</b>: 287ra70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscitranslmed.aaa4">10.1126/scitranslmed.aaa4</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Sci+Transl+Med&amp;rft.atitle=Anti-CD20%2FCD3+T+cell-dependent+bispecific+antibody+for+the+treatment+of+B+cell+malignancies.&amp;rft.volume=7&amp;rft.pages=287ra70&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1126%2Fscitranslmed.aaa4&amp;rft.aulast=Sun&amp;rft.aufirst=LL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kim CH (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816437">"Bispecific small molecule-antibody conjugate targeting prostate cancer"</a>. <i>PNAS</i>. <b>110</b>: 17796–17801. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2013PNAS..11017796K">2013PNAS..11017796K</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1073%2Fpnas.1316026110">10.1073/pnas.1316026110</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3816437">3816437</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PNAS&amp;rft.atitle=Bispecific+small+molecule-antibody+conjugate+targeting+prostate+cancer.&amp;rft.volume=110&amp;rft.pages=17796-17801&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3816437&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.1316026110&amp;rft_id=info%3Abibcode%2F2013PNAS..11017796K&amp;rft.aulast=Kim&amp;rft.aufirst=CH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3816437&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lee, Yong Gu; Chu, Haiyan; Low, Philip S (2017). "Abstract LB-187: New methods for controlling CAR T cell-mediated cytokine storms". <i>Cancer Research</i>. <b>77</b> (13 Supplement): LB-187. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1158%2F1538-7445.AM2017-LB-187">10.1158/1538-7445.AM2017-LB-187</a>. <a rel="nofollow" class="external text" href="https://medicalxpress.com/news/2016-04-t-cell-cancer-treatment.html">Lay summary</a> &#8211; <i>Medical Xpress</i> (April 21, 2016).</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Research&amp;rft.atitle=Abstract+LB-187%3A+New+methods+for+controlling+CAR+T+cell-mediated+cytokine+storms&amp;rft.volume=77&amp;rft.issue=13+Supplement&amp;rft.pages=LB-187&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1158%2F1538-7445.AM2017-LB-187&amp;rft.aulast=Lee&amp;rft.aufirst=Yong+Gu&amp;rft.au=Chu%2C+Haiyan&amp;rft.au=Low%2C+Philip+S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://endocyte.com/technology/smdc/">SMDC TECHNOLOGY</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20160327012636/http://endocyte.com/technology/smdc/">Archived</a> 2016-03-27 at the <a href="/wiki/Wayback_Machine" title="Wayback Machine">Wayback Machine</a> ENDOCYTE</span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://investor.endocyte.com/releasedetail.cfm?releaseid=965753">"Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016"</a> (Press release). Endocyte. April 19, 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">December 20,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Endocyte+Announces+Promising+Preclinical+Data+for+Application+of+SMDC+Technology+in+CAR+T+Cell+Therapy+in+Late-Breaking+Abstract+at+American+Association+for+Cancer+Research+%28AACR%29+Annual+Meeting+2016&amp;rft.pub=Endocyte&amp;rft.date=2016-04-19&amp;rft_id=http%3A%2F%2Finvestor.endocyte.com%2Freleasedetail.cfm%3Freleaseid%3D965753&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><cite class="citation journal">Almåsbak H, Aarvak T, Vemuri MC (2016). <a rel="nofollow" class="external text" href="https://www.hindawi.com/journals/jir/2016/5474602/">"CAR T Cell Therapy: A Game Changer in Cancer Treatment"</a>. <i>Journal of Immunology Research</i>. <b>2016</b>: 5474602. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1155%2F2016%2F5474602">10.1155/2016/5474602</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27298832">27298832</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Immunology+Research&amp;rft.atitle=CAR+T+Cell+Therapy%3A+A+Game+Changer+in+Cancer+Treatment&amp;rft.volume=2016&amp;rft.pages=5474602&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1155%2F2016%2F5474602&amp;rft_id=info%3Apmid%2F27298832&amp;rft.aulast=Alm%C3%A5sbak&amp;rft.aufirst=H&amp;rft.au=Aarvak%2C+T&amp;rft.au=Vemuri%2C+MC&amp;rft_id=https%3A%2F%2Fwww.hindawi.com%2Fjournals%2Fjir%2F2016%2F5474602%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-HO-45"><span class="mw-cite-backlink">^ <a href="#cite_ref-HO_45-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-HO_45-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.medpagetoday.com/HematologyOncology/Lymphoma/68670">Thumbs Up to Latest CAR-T cell Approval - New era for lymphoma, leukemia, possibly other cancers. Oct 2017</a></span>
</li>
<li id="cite_note-news-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-news_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-news_46-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="https://labiotech.eu/car-t-therapy-cancer-review/">"A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology"</a> (Press release). labiotech. March 8, 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">April 19,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=A+Cure+for+Cancer%3F+How+CAR-T+Therapy+is+Revolutionizing+Oncology.&amp;rft.pub=labiotech&amp;rft.date=2018-03-08&amp;rft_id=https%3A%2F%2Flabiotech.eu%2Fcar-t-therapy-cancer-review%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AChimeric+antigen+receptor" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
</ol></div></div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit&amp;section=15" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a rel="nofollow" class="external text" href="https://www.cancer.gov/about-cancer/treatment/research/car-t-cells">CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers</a></li></ul>

<!-- 
NewPP limit report
Parsed by mw1243
Cached time: 20190126154216
Cache expiry: 2073600
Dynamic content: false
CPU time usage: 0.844 seconds
Real time usage: 0.966 seconds
Preprocessor visited node count: 2377/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 109621/2097152 bytes
Template argument size: 1337/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 9/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 147249/5000000 bytes
Number of Wikibase entities loaded: 4/400
Lua time usage: 0.536/10.000 seconds
Lua memory usage: 4.98 MB/50 MB
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  795.629      1 -total
 80.27%  638.642      1 Template:Reflist
 57.51%  457.564     39 Template:Cite_journal
  9.27%   73.776      1 Template:Cite_web
  7.27%   57.841      1 Template:Technical
  6.73%   53.513      3 Template:Ambox
  4.09%   32.569      1 Template:Citation_needed
  3.60%   28.663      1 Template:Fix
  2.03%   16.128      1 Template:Update
  1.76%   14.021      2 Template:Cite_press_release
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1624240-0!canonical and timestamp 20190126154215 and revision id 879808930
 -->
</div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Chimeric_antigen_receptor&amp;oldid=879808930">https://en.wikipedia.org/w/index.php?title=Chimeric_antigen_receptor&amp;oldid=879808930</a>"					</div>
				<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Immune_system" title="Category:Immune system">Immune system</a></li><li><a href="/wiki/Category:T_cells" title="Category:T cells">T cells</a></li><li><a href="/wiki/Category:Cancer_treatments" title="Category:Cancer treatments">Cancer treatments</a></li><li><a href="/wiki/Category:Leukemia" title="Category:Leukemia">Leukemia</a></li><li><a href="/wiki/Category:Lymphoma" title="Category:Lymphoma">Lymphoma</a></li><li><a href="/wiki/Category:Gene_therapy" title="Category:Gene therapy">Gene therapy</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Webarchive_template_wayback_links" title="Category:Webarchive template wayback links">Webarchive template wayback links</a></li><li><a href="/wiki/Category:Wikipedia_articles_that_are_too_technical_from_April_2018" title="Category:Wikipedia articles that are too technical from April 2018">Wikipedia articles that are too technical from April 2018</a></li><li><a href="/wiki/Category:All_articles_that_are_too_technical" title="Category:All articles that are too technical">All articles that are too technical</a></li><li><a href="/wiki/Category:Articles_needing_expert_attention_from_April_2018" title="Category:Articles needing expert attention from April 2018">Articles needing expert attention from April 2018</a></li><li><a href="/wiki/Category:All_articles_needing_expert_attention" title="Category:All articles needing expert attention">All articles needing expert attention</a></li><li><a href="/wiki/Category:Wikipedia_articles_in_need_of_updating_from_October_2016" title="Category:Wikipedia articles in need of updating from October 2016">Wikipedia articles in need of updating from October 2016</a></li><li><a href="/wiki/Category:All_Wikipedia_articles_in_need_of_updating" title="Category:All Wikipedia articles in need of updating">All Wikipedia articles in need of updating</a></li><li><a href="/wiki/Category:Articles_needing_additional_references_from_August_2017" title="Category:Articles needing additional references from August 2017">Articles needing additional references from August 2017</a></li><li><a href="/wiki/Category:All_articles_needing_additional_references" title="Category:All articles needing additional references">All articles needing additional references</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_December_2017" title="Category:Articles with unsourced statements from December 2017">Articles with unsourced statements from December 2017</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
									<div id="p-personal" role="navigation" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Chimeric+antigen+receptor" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Chimeric+antigen+receptor" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
							<li id="ca-nstab-main" class="selected"><span><a href="/wiki/Chimeric_antigen_receptor" title="View the content page [c]" accesskey="c">Article</a></span></li><li id="ca-talk"><span><a href="/wiki/Talk:Chimeric_antigen_receptor" rel="discussion" title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>						</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-variants-label" />
						<h3 id="p-variants-label">
							<span>Variants</span>
						</h3>
						<ul class="menu">
													</ul>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
							<li id="ca-view" class="collapsible selected"><span><a href="/wiki/Chimeric_antigen_receptor">Read</a></span></li><li id="ca-edit" class="collapsible"><span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=edit" title="Edit this page [e]" accesskey="e">Edit</a></span></li><li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=history" title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>						</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-cactions-label" />
						<h3 id="p-cactions-label"><span>More</span></h3>
						<ul class="menu">
													</ul>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>
						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
								<input type="search" name="search" placeholder="Search Wikipedia" title="Search Wikipedia [f]" accesskey="f" id="searchInput"/><input type="hidden" value="Special:Search" name="title"/><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton"/><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton"/>							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page" title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id="p-navigation" aria-labelledby="p-navigation-label">
			<h3 id="p-navigation-label">Navigation</h3>
			<div class="body">
								<ul>
					<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-interaction" aria-labelledby="p-interaction-label">
			<h3 id="p-interaction-label">Interaction</h3>
			<div class="body">
								<ul>
					<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-tb" aria-labelledby="p-tb-label">
			<h3 id="p-tb-label">Tools</h3>
			<div class="body">
								<ul>
					<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Chimeric_antigen_receptor" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Chimeric_antigen_receptor" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;oldid=879808930" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q5099363" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Chimeric_antigen_receptor&amp;id=879808930" title="Information on how to cite this page">Cite this page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-coll-print_export" aria-labelledby="p-coll-print_export-label">
			<h3 id="p-coll-print_export-label">Print/export</h3>
			<div class="body">
								<ul>
					<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Chimeric+antigen+receptor">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:ElectronPdf&amp;page=Chimeric+antigen+receptor&amp;action=show-download-screen">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Chimeric_antigen_receptor&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-lang" aria-labelledby="p-lang-label">
			<h3 id="p-lang-label">Languages</h3>
			<div class="body">
								<ul>
					<li class="interlanguage-link interwiki-ar"><a href="https://ar.wikipedia.org/wiki/%D9%85%D8%B3%D8%AA%D9%82%D8%A8%D9%84_%D9%85%D8%B3%D8%AA%D8%B6%D8%AF_%D8%AE%D9%8A%D9%85%D8%B1%D9%8A" title="مستقبل مستضد خيمري – Arabic" lang="ar" hreflang="ar" class="interlanguage-link-target">العربية</a></li><li class="interlanguage-link interwiki-cs"><a href="https://cs.wikipedia.org/wiki/Chimern%C3%AD_antigenn%C3%AD_receptor" title="Chimerní antigenní receptor – Czech" lang="cs" hreflang="cs" class="interlanguage-link-target">Čeština</a></li><li class="interlanguage-link interwiki-de"><a href="https://de.wikipedia.org/wiki/CAR-T-Zell-Therapie" title="CAR-T-Zell-Therapie – German" lang="de" hreflang="de" class="interlanguage-link-target">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="https://es.wikipedia.org/wiki/Receptor_de_ant%C3%ADgeno_quim%C3%A9rico" title="Receptor de antígeno quimérico – Spanish" lang="es" hreflang="es" class="interlanguage-link-target">Español</a></li><li class="interlanguage-link interwiki-fr"><a href="https://fr.wikipedia.org/wiki/R%C3%A9cepteur_antig%C3%A9nique_chim%C3%A9rique" title="Récepteur antigénique chimérique – French" lang="fr" hreflang="fr" class="interlanguage-link-target">Français</a></li><li class="interlanguage-link interwiki-nl"><a href="https://nl.wikipedia.org/wiki/CAR-T" title="CAR-T – Dutch" lang="nl" hreflang="nl" class="interlanguage-link-target">Nederlands</a></li><li class="interlanguage-link interwiki-ja"><a href="https://ja.wikipedia.org/wiki/%E3%82%AD%E3%83%A1%E3%83%A9%E6%8A%97%E5%8E%9F%E5%8F%97%E5%AE%B9%E4%BD%93" title="キメラ抗原受容体 – Japanese" lang="ja" hreflang="ja" class="interlanguage-link-target">日本語</a></li><li class="interlanguage-link interwiki-ru"><a href="https://ru.wikipedia.org/wiki/%D0%A5%D0%B8%D0%BC%D0%B5%D1%80%D0%BD%D1%8B%D0%B9_%D0%B0%D0%BD%D1%82%D0%B8%D0%B3%D0%B5%D0%BD%D0%BD%D1%8B%D0%B9_%D1%80%D0%B5%D1%86%D0%B5%D0%BF%D1%82%D0%BE%D1%80" title="Химерный антигенный рецептор – Russian" lang="ru" hreflang="ru" class="interlanguage-link-target">Русский</a></li><li class="interlanguage-link interwiki-sl"><a href="https://sl.wikipedia.org/wiki/Himerni_antigenski_receptor" title="Himerni antigenski receptor – Slovenian" lang="sl" hreflang="sl" class="interlanguage-link-target">Slovenščina</a></li>				</ul>
				<div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q5099363#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
				<div id="footer" role="contentinfo">
						<ul id="footer-info">
								<li id="footer-info-lastmod"> This page was last edited on 23 January 2019, at 14:50<span class="anonymous-show">&#160;(UTC)</span>.</li>
								<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//foundation.wikimedia.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//foundation.wikimedia.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
							</ul>
						<ul id="footer-places">
								<li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
								<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
								<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
								<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
								<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
								<li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Cookie_statement">Cookie statement</a></li>
								<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Chimeric_antigen_receptor&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
							</ul>
										<ul id="footer-icons" class="noprint">
										<li id="footer-copyrightico">
						<a href="https://wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>					</li>
										<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="/static/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x" width="88" height="31"/></a>					</li>
									</ul>
						<div style="clear: both;"></div>
		</div>
		
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.844","walltime":"0.966","ppvisitednodes":{"value":2377,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":109621,"limit":2097152},"templateargumentsize":{"value":1337,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":9,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":147249,"limit":5000000},"entityaccesscount":{"value":4,"limit":400},"timingprofile":["100.00%  795.629      1 -total"," 80.27%  638.642      1 Template:Reflist"," 57.51%  457.564     39 Template:Cite_journal","  9.27%   73.776      1 Template:Cite_web","  7.27%   57.841      1 Template:Technical","  6.73%   53.513      3 Template:Ambox","  4.09%   32.569      1 Template:Citation_needed","  3.60%   28.663      1 Template:Fix","  2.03%   16.128      1 Template:Update","  1.76%   14.021      2 Template:Cite_press_release"]},"scribunto":{"limitreport-timeusage":{"value":"0.536","limit":"10.000"},"limitreport-memusage":{"value":5226717,"limit":52428800}},"cachereport":{"origin":"mw1243","timestamp":"20190126154216","ttl":2073600,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":114,"wgHostname":"mw1272"});});</script>
	</body>
</html>
